InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Sunday, 02/16/2014 10:08:09 PM

Sunday, February 16, 2014 10:08:09 PM

Post# of 346001
Catalysts?TIME forANOTHER POTENTIAL NEWS LIST forNEWBIES UPDATE

There is a lot of news to come. For an interesting discussion of many of these points(more chronological) I recommend you read golfho's post #155982

Which of the following might these releases concern?

1. Bavi Oncology partnership

2. Liver cancer IST results. There are interim results to be released at a scientific conference in March.

3. Liver cancer partnership

4. Cotara partnership announcement

5. Breast cancer IST results

6. Breast cancer advancing in clinic

7. Ambulance Chaser Lawsuit ended(completely!).

8. CSM settlement

9. Betabodies preclinical

10. Bavi plus other immunotherapies preclinical results...we already have some very interesting Bavi plus Yervoy preclinical results. But there is more to come.In recent presentations PPHM has mentioned 12 or more potential Bavi/immunotherapy combinations. That does not rule out the potential of a cocktail of several of these being used together. So far we have only seen some results from the Bavi/Yervoy preclinical combination. Obviously there is a lot more news to come.

a.anti-CTLA-4 (Yervoy)
b.anti-PD-1
c.anti-PD-L1
d.anti-TGF-b
e.anti-IL-10
f.GM-CSF
g.IFN-a
h.IL-2
i.Provenge
j.other vaccines
k.appropriate TKI
l.radiation plus androgen deprivation
m.anti-CD47 and anti-CD54. Abstract presented at AAI May 2013.

11. Bavi plus immunotherapy clinical trials. Bavi/Yervoy Phase I could start in January 2014. More could come.

12. Dr. Brekken announcements(publications,editorials,presentations). An article appeared in a prestigious EU publication in December. More to come.

13. Another Govt. deal for viruses? HIV presentation in March.

14. Breakthrough, Accelerated Approval or Priority Review announcements?

15. Imaging data update

16. New analyst coverage?

17. Institutional ownership increase?

18. Fast track for second line NSCLC announced in January. AA and PR could follow.

19. Sale of Series E Preferred Convertible shares has now increased the companies cash to some $90 million. More financing news to come...

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News